Cargando…

抗PD-1/PD-L1单抗治疗肺癌临床研究进展

Recently, the immune checkpoint inhibitors which target programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have made a breakthrough in the treatment of advanced non-small cell lung cancer. Researches on immune checkpoint inhibitors have been rapidly implemented in various types of lung cancer, such as sm...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000315/
https://www.ncbi.nlm.nih.gov/pubmed/26582228
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.11.09